Survival of pancreatic cancer cells lacking KRAS function
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...
Main Authors: | , , , , , , , , , |
---|---|
Other Authors: | , |
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group,
2017-12-11T19:48:01Z.
|
Subjects: | |
Online Access: | Get fulltext |